SE0402520D0 - Method - Google Patents

Method

Info

Publication number
SE0402520D0
SE0402520D0 SE0402520A SE0402520A SE0402520D0 SE 0402520 D0 SE0402520 D0 SE 0402520D0 SE 0402520 A SE0402520 A SE 0402520A SE 0402520 A SE0402520 A SE 0402520A SE 0402520 D0 SE0402520 D0 SE 0402520D0
Authority
SE
Sweden
Prior art keywords
par3
asthma
csf
tnf
antagonists
Prior art date
Application number
SE0402520A
Other languages
Swedish (sv)
Inventor
Rajinder Beri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0402520A priority Critical patent/SE0402520D0/en
Publication of SE0402520D0 publication Critical patent/SE0402520D0/en
Priority to PCT/SE2005/001547 priority patent/WO2006054931A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of antagonists of a protease- activated receptor, PAR3, for the treatment of asthma. The presence of pro- inflammatory cytokines, such as TNF- alpha or ILl-beta, thrombin interacts with PAR3 resulting in the induction of GM-CSF to a level that is found in asthma.
SE0402520A 2004-10-18 2004-10-18 Method SE0402520D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0402520A SE0402520D0 (en) 2004-10-18 2004-10-18 Method
PCT/SE2005/001547 WO2006054931A1 (en) 2004-10-18 2005-10-17 The use and identification of antagonists of protease-activated receptor 3 (par3) in the treatment of asthma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402520A SE0402520D0 (en) 2004-10-18 2004-10-18 Method

Publications (1)

Publication Number Publication Date
SE0402520D0 true SE0402520D0 (en) 2004-10-18

Family

ID=33448650

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402520A SE0402520D0 (en) 2004-10-18 2004-10-18 Method

Country Status (2)

Country Link
SE (1) SE0402520D0 (en)
WO (1) WO2006054931A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083864A1 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 3 (par3)

Also Published As

Publication number Publication date
WO2006054931A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NL301145I2 (en) Tirbanibulin
NL301089I2 (en) imlifidase
NO20054371L (en) Somatostatin-dopamine chimeric analogs
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
EA201170521A1 (en) NEW CONNECTIONS
DE602005020799D1 (en) HUMANIZED ANTI-CMET ANTAGONISTS
TW200801006A (en) Fused bicyclic mTOR inhibitors
DK3530673T3 (en) Humanized anti-beta7 antagonists and uses thereof
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
MX2009008104A (en) Hepcidin, hepcidin antagonists and methods of use.
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
ATE497492T1 (en) CLEANING MONTELUKAST
TW200700064A (en) Novel compounds
ATE484501T1 (en) BENZIMIDAZOLES USABLE AS PROTEIN KINASE INHIBITORS
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
GB0426313D0 (en) Therapeutic agents
ATE475651T1 (en) ARYL-SUBSTITUTED HETEROCYCLES AND THEIR USE
NO20075662L (en) Roflumilast for the treatment of pulmonary hypertension
ATE410235T1 (en) TREATMENT OF BALLAST WATER
ATE455789T1 (en) SUBSTITUTED NONADEPSIPEPTIDES
ATE410443T1 (en) HETEROCYCLYL-SUBSTITUTED NONADEPSIPEPTIDES
EA201001872A1 (en) NEW WAYS TO OBTAIN CYCLOPROPYLAMIDE DERIVATIVES
CY1109803T1 (en) PHARMACEUTICAL COMPOSITES BASED ON NK2 COMPONENTS FOR PEDIATRIC USE
SE0402520D0 (en) Method
DE602004019541D1 (en) CYCLOALKYLÄBÜ CONDENSED INDOLE